Moore, David H <br/><br/>
Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Nov 2003 
 - 4207-13 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2003.02.086  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Amifostine--therapeutic use<br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Breast Neoplasms--drug therapy<br/>Cisplatin--administration & dosage<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Middle Aged<br/>Neurologic Examination<br/>Paclitaxel--administration & dosage<br/>Peripheral Nervous System Diseases--chemically induced<br/>Radiation-Protective Agents--therapeutic use<br/>Treatment Outcome